Marker Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Marker Therapeutics Director Katharine Knobil received grants of 221,741 stock options as compensation for her service.
NASDAQ
Marker Therapeutics director Norman David Eansor received 221,741 stock options for his service in 2024 and 2025 under the company's 2020 Omnibus Stock Ownership Plan.
NASDAQ
Marker Therapeutics Director Steve Elms received grants of 221,741 stock options for his service in 2024 and 2025.
NASDAQ
Marker Therapeutics Director Kathryn Penkus Corzo was granted 147,611 stock options with an exercise price of $0.9877, vesting over 36 months.
NASDAQ
Marker Therapeutics, Inc. CEO Juan Vera was granted 250,000 employee stock options with an exercise price of $0.9877.
NASDAQ
Director Steve Elms acquired 30,000 stock options in Marker Therapeutics, Inc. on February 12, 2025, according to a Form 4 filing.
NASDAQ
Director Katharine Knobil received stock options for 30,000 shares of Marker Therapeutics, Inc. at an exercise price of $1.59 on February 12, 2025.
NASDAQ
Norman David Eansor, a director of Marker Therapeutics, Inc., was granted stock options to purchase 30,000 shares of common stock.
NASDAQ
Juan Vera, President and CEO of Marker Therapeutics, acquired 50,000 employee stock options on February 12, 2025, according to a Form 4 filing.
NASDAQ
Director Steve Elms reports acquisition of Marker Therapeutics common stock via a Securities Purchase Agreement.
NASDAQ
New Enterprise Associates 16, L.P. acquired 554,250 shares of Marker Therapeutics, Inc. at $3.20 per share on December 23, 2024, increasing its holdings to 1,625,678 shares.